anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:The titled composition, containing powder of Paeonia albiflora Pall. (peony) or Paeonia suffruticosa Andr. or an aqueous extract thereof, etc., and capable of exhibiting improved effect on the improvement of skin roughening, liver-spot, ephelis, pimple, itching, etc. in the form of a cream, nursery powder, soap, etc. CONSTITUTION:The titled composition containing powder of Paeonia albiflora Pall, (peony) or Paeonia suffruticosa Andr. or an aqueous extract thereof as an essential component. The crude drug component has a long history as an internal medicine and high safety. Furthermore, the continuous use thereof contained in a cosmetic has improved effect on the improvement of skin roughening, liver-spot, ephelis, pimple, itching, etc., and suitable for the drug component to be mixed with the cosmetic generally in continuous use.  The Paeonia albiflora Pall. in the component is the dried root thereof, and the Paeonia suffruticosa Andr. is the dried root bark thereof. The aqueous extract is obtained by extracting the root or root bark with water or aqueous alcohol, e.g. 30% ethanol, at 15-25 deg.C, and the mixing ratio is 0.005-2wt% based on the total crude drug.
In one example, the disclosure relates to a catheter system comprising an elongated body defining a lumen. The elongated body comprising a proximal portion and a distal portion. An anchoring member is positioned on the proximal portion of the elongated body. The anchoring member configured to anchor the proximal portion of the elongated body to a patient. The catheter system includes one or more sensors positioned on the elongated body. The one or more sensors are configured to sense a parameter of a fluid within the lumen of the elongated body. The catheter system includes memory positioned on the elongated body, the memory configured to store patient-specific information.
Children with Duchenne Muscular Dystrophy who are between Levels 1-4 (continuing ambulation) according to Brooke Lower Extremity Functional Classification will be included in the study. This classification method was designed on the basis of the classification method to determine the functional status of the lower and upper extremities in the clinical evaluation of Duchenne Muscular Dystrophy.
VIVITROL® (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, to be administered by deep intramuscular injection by a healthcare practitioner. VIVITROL contains naltrexone base anhydrous as the active pharmaceutical ingredient. Naltrexone is an opioid antagonist with little, if any, opioid agonist activity. 

Naltrexone is morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-(5α) (CAS Registry # 16590-41-3). The molecular formula is C20H23NO4 and its molecular weight is 341.41 in the anhydrous form (ie, < 1% maximum water content). The structural formula is: 

Naltrexone base anhydrous is an off-white to a light tan powder with a melting point of 168 °C to 170 °C (334 °F to 338 °F). It is insoluble in water and is soluble in ethanol. 

VIVITROL is provided in a carton containing one vial of VIVITROL microspheres, one vial of diluent, one 5-mL syringe, one 1-inch 20-gauge preparation needle, two 1 1/2-inch 20-gauge, and two 2-inch 20-gauge administration needles with needle protection device. 

VIVITROL microspheres consist of a sterile, off-white to light tan powder that is available in a dosage strength of 380 mg of naltrexone per vial. Naltrexone base anhydrous is incorporated in a biodegradable matrix of 75:25 polylactide-co-glycolide (PLG) at a concentration of 337 mg of naltrexone per gram of microspheres. 

The diluent is a clear, colorless solution. Each mL of diluent contains 30.0 mg of carboxymethylcellulose sodium, 1.0 mg of polysorbate 20, 9.0 mg of sodium chloride, and sodium hydroxide and hydrochloric acid as pH adjusters, in water for injection. The pH of the diluent is in the range of 5.8 to 7.2.
Behavioral weight loss core intervention, includes activity tracker, wireless scale, daily self-weighing, and smartphone app with weekly behavioral lessons, food tracking log, weekly tailored feedback summary, and daily weight-related behavioral goals. Core intervention component is combined with each of the 7 intervention messages to be tested repeatedly over time.
Participants are prescribed a Physical activity on Prescription (PaP) which means that they will have a motivational interview with a physiotherapist regarding increased physical activity. The physiotherapist will then prescribe a individualized PaP with the goal to increase weekly physical activity that the participant are instructed to adhere to for the remainder of the study. A follow-up session is also included after 16 weeks. Participants are invited to a 16 week exercise intervention at a private fitness center after they have received their PaP. The exercise, including a variety of aerobic and resistance training, is performed in a group setting starting with one session per week for the first two weeks and then two sessions per week for week 3-16. Follow-up tests is also included after 6-, 12- and 24 months.
Our aim is to investigate whether reduced exercise capacity, increased respiratory drive and dyspnoea are linked to heightened sympathetic activation at rest and during exercise in patients with COPD. Furthermore, the effect of unloading the respiratory muscles by using non-invasive ventilation (NIV) will be assessed. Fifteen stable COPD patients without NIV will be matched to 15 healthy control subjects (with sufficient microneurography recording). Furthermore COPD patients on regular NIV will be studied. Each participant will undergo symptom limited bicycle exercise and a handgrip protocol. Microneurography will be used to quantify sympathetic activity by the transcutaneous registration of postganglionic sympathetic efferents.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic, capable of activating functions of skin without damaging the skin, assisting the regeneration of the skin and manifesting excellent effects even on reduction in fine wrinkles, dermal stains and skin roughening by formulating an extract liquid or a pressed liquid from a fruit of an Ume (a Japanese apricot) of the family Rosaceae therewith. SOLUTION: This cosmetic is obtained by formulating (A) a cosmetic base for skin, hair or a bathing agent with (B) an extract liquid or a pressed liquid of (B0 ) a fruit of an Ume  a Japanese apricot (Prunus mume SIEB. et. Zucc.)} of the family Rosaceae in an amount of, e.g. 0.1-25 wt.%, expressed in terms of the solid content and based on the ingredient A. The ingredient B is obtained by directly pressing, e.g. the ingredient B0 or shredding the ingredient B0 and extracting the shredded ingredient B0 with water or an organic solvent such as 1,3-butylene glycol or ethanol alone or a mixture thereof at normal temperatures or under heating.
The intricate cooperation between cancer cells and nontumor stromal cells within melanoma microenvironment (MME) enables tumor progression and metastasis. We previously demonstrated that the interplay between tumor-associated macrophages (TAMs) and melanoma cells can be disrupted by using long-circulating liposomes (LCLs) encapsulating prednisolone phosphate (PLP) (LCL-PLP) that inhibited tumor angiogenesis coordinated by TAMs. In this study, our goal was to improve LCL specificity for protumor macrophages (M2-like (i.e., TAMs) macrophages) and to induce a more precise accumulation at tumor site by loading PLP into IL-13-conjugated liposomes (IL-13-LCL-PLP), since IL-13 receptor is overexpressed in this type of macrophages. The IL-13-LCL-PLP liposomal formulation was obtained by covalent attachment of thiolated IL-13 to maleimide-functionalized LCL-PLP. C57BL/6 mice bearing B16.F10 s.c melanoma tumors were used to investigate the antitumor action of LCL-PLP and IL-13-LCL-PLP. Our results showed that IL-13-LCL-PLP formulation remained stable in biological fluids after 24h and it was preferentially taken up by M2 polarized macrophages. IL-13-LCL-PLP induced strong tumor growth inhibition compared to nonfunctionalized LCL-PLP at the same dose, by altering TAMs-mediated angiogenesis and oxidative stress, limiting resistance to apoptosis and invasive features in MME. These findings suggest IL-13-LCL-PLP might become a promising delivery platform for chemotherapeutic agents in melanoma.
At the end of either control or intervention arm, participants will have a washout period of 2 weeks, after which participants will be crossed over to the other group for the subsequent 4 weeks. For example, after Participant AB is in intervention arm for 4 weeks, he/she will then have a wash out period of 2 weeks in which they will return to their usual state of living. At the end of the washout period, the participant AB will be put in the control arm for 4 weeks.
Northern corn leaf blight, caused by Exserohilum turcicum, is mainly controlled by the use of resistant cultivars. Maize lines carrying individual resistance genes B37Ht1, B37Ht2, B37Ht3, and B37Htn1 express different defense symptoms having an impact on the photosynthetic activity, the accumulation of reactive oxygen species, and epidemiological parameters. Plants were inoculated with a race 0 isolate of E. turcicum conferring a compatible interaction with B37 and incompatible interactions with plants carrying resistance genes. Five days postinoculation (dpi), the resistant lines displayed a reduction in leaf CO2 assimilation of 30 to 80% compared with healthy plants. At 14 dpi, inoculated plants of B37Ht1 showed a significant decrease in leaf CO2 assimilation, similar to B37 (up to 94%). The instantaneous carboxylation efficiency was significantly reduced on inoculated plants of the lines B37Ht2, B37Ht3, and B37Htn1 (54 to 81%) at 5 dpi. Curiously, the reduction in carboxylation efficiency for B37 and B37Ht1 (up to 95%) was higher at 14 dpi than at 5 dpi (up to 81%). At 6 dpi, low levels of H2O2 were detected in B37Ht1, in contrast to B37Htn1, where a high H2O2 level and peroxidase activity were observed. The sporulation rate on B37Ht1, B37Ht3, and B37Htn1 decreased by 92% compared with the susceptible control, whereas strong sporulation occurred in lesions on line B37Ht2. The resistance in maize to E. turcicum conferred by Ht resistance genes is associated with photosynthetic costs and may have quite contrasting effects on host physiology and major epidemiological parameters, such as sporulation, which contributes inoculum for secondary infections.
In clinical studies, finasteride tablets reduced serum PSA concentration by approximately 50% within six months of treatment. This decrease is predictable over the entire range of PSA values in patients with symptomatic BPH, although it may vary in individuals.

For interpretation of serial PSAs in men taking finasteride tablets, a new PSA baseline should be established at least six months after starting treatment and PSA monitored periodically thereafter. Any confirmed increase from the lowest PSA value while on finasteride tablets may signal the presence of prostate cancer and should be evaluated, even if PSA levels are still within the normal range for men not taking a 5α-reductase inhibitor. Non-compliance with finasteride tablets therapy may also affect PSA test results. To interpret an isolated PSA value in patients treated with finasteride tablets for six months or more, PSA values should be doubled for comparison with normal ranges in untreated men. These adjustments preserve the utility of PSA to detect prostate cancer in men treated with finasteride tablets.

Finasteride tablets may also cause decreases in serum PSA in the presence of prostate cancer.

The ratio of free to total PSA (percent free PSA) remains constant even under the influence of finasteride tablets. If clinicians elect to use percent free PSA as an aid in the detection of prostate cancer in men undergoing finasteride therapy, no adjustment to its value appears necessary.
Human Experience:Experience with zonisamide daily doses over 800 mg/day is limited. During zonisamide clinical development, three patients ingested unknown amounts of zonisamide as suicide attempts, and all three were hospitalized with CNS symptoms. One patient became comatose and developed bradycardia, hypotension, and respiratory depression; the zonisamide plasma level was 100.1 mcg/mL measured 31 hours post-ingestion. Zonisamide plasma levels fell with a half-life of 57 hours, and the patient became alert five days later. 

Management:No specific antidotes for zonisamide overdosage are available. Following a suspected recent overdose, emesis should be induced or gastric lavage performed with the usual precautions to protect the airway. General supportive care is indicated, including frequent monitoring of vital signs and close observation. 

Zonisamide has a long half-life (see CLINICAL PHARMACOLOGY section). Due to the low protein binding of zonisamide (40%), renal dialysis may be effective. The effectiveness of renal dialysis as a treatment of overdose has not been formally studied. A poison control center should be contacted for information on the management of zonisamide overdosage.
Retrospective patient data will be obtained by querying the Opera operating room database of both study institutions. Electronic records will be analyzed for all patients undergoing a first-time ileocolic resection for Crohn's Disease between January 1, 2009 - December 31, 2018.
The invention relates to a traditional Chinese medicine oral liquid for treating bacterial enteritis of fishes and a preparation method thereof. The traditional Chinese medicine oral liquid is prepared from the root of kudzu vine, amur corktree bark, coptis chinensis, Chinese pulsatilla roots, ash bark, bletilla striata and tree peony bark. The traditional Chinese medicine composition can be oral liquid. The traditional Chinese medicine oral liquid is prepared through the following steps: (1), smashing traditional Chinese medicines to 60-80 meshes, weighing according to the formula ratio, and three-dimensionally mixing to obtain traditional Chinese medicine powder; (2), feeding the mixed traditional Chinese medicine powder and 300-600 parts of water into an extracting tank respectively for soaking for 5-20 h; (3), heating to 40-100 DEG C and extracting for 10-15 h; (4), filtering and collecting a medical solution; (5), continuously adding 300-600 parts of water into rest medicine dregs and extracting for 10-15 h at 40-100 DEG C; (6), filtering to remove medicine dregs, mixing the two extracting solutions, concentrating the mixed extracting solution at 30-70 DEG C under reduced pressure until the volume of the mixed extracting solution is 10%-20% of original volume; (7), filling bottles with the concentrated extracting solution in a manner that each bottle is filled with 250 ml of the concentrated extracting solution, so as to obtain the finished product. The traditional Chinese medicine oral liquid provided by the invention can effectively treat bacterial enteritis of fishes, and the cure rate reaches 90% or above. The traditional Chinese medicine oral liquid has the effects of clearing heat, stopping dysentery, cooling blood and hemostasis, promoting spleen yang and stopping diarrhea.
Evaluation of the efficacy and safety of methylprednisolone combined with abrocitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with Arocitinib 200 mg daily.
Preterm labor is defined as regular contractions of the uterus resulting in changes in the cervix (effacement and dilatation) that start before 37 weeks of pregnancy. (1) Although preterm labor constitutes only 10% of total labors, yet 70% of infant's mortality is related to prematurity. It is therefore one of the international indices in assessment of health condition worldwide. Factors that increase the risk of preterm birth include history of previous preterm birth, short cervix, short time between pregnancies, teenage pregnancy, history of certain types of surgery on the uterus or cervix, certain pregnancy complications, such as multiple pregnancy and vaginal bleeding and lifestyle factors such as low pre-pregnancy weight, smoking during pregnancy, and substance abuse during pregnancy.

Preterm labor can be diagnosed clinically only when changes in the cervix are found after pelvic examination along with contractions also may be monitored. A transvaginal ultrasound exam may be done to measure the length of your cervix. Tocolytics are drugs used to delay delivery for a short time (up to 48 hours). They may allow time for corticosteroids or magnesium sulfate to be given or for you to be transferred to a hospital that offers specialized care for preterm infants. (1,2) Tocolytic agents are β- HCG, MgSO4, nifedipine, β-agonists(salbutamol) and atosiban. Use of salbutamol is of limited use because of many cardiovascular complications i.e., ventricular arrythmia, hypertension and hyperglycemia while atosiban is expensive and not available in Pakistan.

Human Chorionic Gonadotropin (H.C.G.) is a heterodimeric glycoprotein produced primarily in the placenta and has multiple endocrines, paracrine and immunoregulatory actions. (3) The importance of H.C.G. in maintenance of early pregnancy has been widely accepted, reports have highlighted a potential role of H.C.G. in maintaining uterine quiescence in the third trimester. H.C.G. exerts a potent concentration dependent inhibitory effect on human myometrial contractions. (4) Recent data suggests that H.C.G. might have a role as an endogenous tocolytic agent in normal pregnancy. A significant decrease in serum H.C.G. level was found 2-3 weeks before the spontaneous onset of labour. This might contribute to increasing the contractility in the uterine muscle and gradually initiating the onset of labour. (5) Following I.M. injection, peak concentration of H.C.G. occurs about 6 hrs after a dose. It is distributed primarily to gonads. Blood concentration declines in a biphasic manner, with a half-life between about 6 and 11 hrs and 23 to 38 hrs respectively. About 10 to 12% of an IM dose is excreted in urine within 24 hours. (6)
Sickle cell anemia is an autosomal recessive disorder and the most common genetic disease affecting African-Americans. Approximately 0.15% of African-Americans are homozygous for sickle cell disease, and 8% have sickle cell trait. Acute pain crisis, acute chest syndrome (ACS), and secondary pulmonary hypertension are common complications of sickle cell anemia. Mortality rates of sickle cell patients with pulmonary hypertension are significantly increased as compared to patients without pulmonary hypertension. Recent studies report up to 40% mortality at 22 months after detection of elevated pulmonary artery pressures in sickle cell patients. Furthermore, pulmonary hypertension is thought to occur in up to 30% of clinic patients with sickle cell anemia.

This study is designed to determine the prevalence and prognosis of secondary pulmonary hypertension in adult patients with sickle cell anemia, and to determine whether genetic polymorphisms in candidate genes contribute to its development or response to treatment.
Lung transplantation has emerged as a viable therapeutic option in the care of patients with advanced pulmonary parenchymal and pulmonary vascular disease. Currently, over 10,000 patients have received lung transplantation with approximately 1200 transplant operations performed worldwide each year. Short-term survival after lung transplantation has continued to improve since the widespread application of this procedure and one-year survival at most centers now approaches 80%. Unfortunately, long-term outcomes after lung transplantation are disappointing with five-year survival below 50%. Most posttransplant deaths are due directly or indirectly to the development of acute or chronic rejection. Acute rejection is defined by the presence of perivascular mononuclear inflammatory cells. Obliterative bronchiolitis (OB) describes fibrosis and obliteration of the small to medium size bronchioles, the histological manifestation of chronic lung rejection. Bronchiolitis obliterans syndrome (BOS) is thought to correlate with the development of histological OB when other causes of allograft dysfunction have been excluded. The diagnosis of OB is based primarily on a decline in spirometry with exclusion of alternative diagnoses with bronchoscopy and biopsy, i.e. development of clinical BOS. Since the introduction of BOS nomenclature, numerous studies have validated the clinical and prognostic importance of this syndrome and verified its correlation with histological OB.

Chronic rejection describes a histological pattern of fibrous obliteration of endothelial or epithelial structures in the allograft. A similar pattern of histological fibrosis is observed in all types of solid organ transplants (e.g., obliterative arteriopathy in heart transplant, BOS in lung transplant), and occurs despite the use of currently available, primarily T-cell based, immune suppression. The rates of chronic rejection vary considerably with the type of organ transplanted. By five years after transplantation histological fibrosis occurs in approximately 20% of kidney, 40% of heart and 60-80% of lung recipients. Thus, lung transplantation is characterized by an unusually high incidence of chronic graft rejection manifest as BOS.

Because of the high rate of acute and chronic lung transplant rejection, research designed to better correlate clinical outcomes with the genetic risks for rejection is critical to improving patient outcomes. We recently completed a study that demonstrated two single nucleotide polymorphisms (SNPs) Asp299Gly and Thr399Ile (polymorphisms of the human Toll 4 gene associated with endotoxin hyporesponsiveness) were associated with decreased acute rejection after lung transplantation.

We hypothesize that other SNPs associated with either increased or decreased innate or adaptive immune activation will be critical to determining the clinical outcome with regards to acute and chronic rejection after lung transplant. If specific genetic risks for rejection after transplant could be identified, this might lead to highly tailored immunosuppressive regimens and improved clinical outcomes.
The history behind the biological, mechanistic, and clinical insights into concussion provides awareness of the current understanding and future areas for study. Although the initial description of concussion appeared in the 10th century, the potential long-term structural consequences were first defined by Harrison Martland, M.D., who performed a postmortem study of former boxers in 1928. He found evidence of perivascular microhemorrhage that he believed eventually evolved into a "replacement gliosis" underlying a clinical syndrome that he named "punch drunk," which was characterized by acute confusion with chronic cognitive and physical symptoms developing in those with prolonged exposure. Further research into the potential long-term consequences of repetitive concussions, particularly in athletics and the military, led to an understanding of chronic traumatic encephalopathy. To ameliorate possible long-term risks, research has been focused on preventative and therapeutic measures for concussion. In this review article, the authors present the history of concussion and the long-term sequelae of repeated head injury. Specifically, they consider how the understanding of concussion has evolved from antiquity into the modern era, and how this change in understanding of head injury has led to an appreciation of the fact that its long-term implications sometimes manifest as the clinical and histopathological entity of chronic traumatic encephalopathy.